

Please type a plus sign (+) inside this box → ☐

JAN 13 2003

Approved for use through 10/31/2004. OMB 0651-0047  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/023,603
				Filing Date	December 17, 2001
				First Named Inventor	Snyder et al.
				Group Art Unit	1646 1623
				Examiner Name	N/A L. Maier
Sheet	1	of	1	Attorney Docket Number	18085.105229 (EMU2090US)

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
LCM	AA	WO	95/14025		Merck & Co.	26-05-1995		
LCM	AB	WO	95/02587		Merck & Co.	26-01-1995		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
LCM	AC	CHAABAN, <i>Scientia Pharmaceutica</i> , vol. 48, no. 4, 1980, 356-65, abstract no. 94:150965 CAS. <i>abstract only</i>	
LCM	AD	DAI, <i>J. of Organic Chemistry</i> , vol. 63, no. 8, 1998, pp. 2597-2600, abstract no. 128:321740 CAS. <i>abstract only</i>	
LCM	AE	DEVGAN, <i>J. of Indian Chem. Society</i> , vol. 44, no. 9, 1967, 776-779, abstract no. 68:95475, CAS. <i>abstract only</i>	
LCM	AF	KIRMSE, <i>Chemische Berichte</i> , vol. 105, no. 8, 1972, pp. 2746-2753, abstract no. 126850, CAS. <i>abstract only</i>	
LCM	AG	KIRMSE, <i>Angewandte Chemie</i> , vol. 9, no. 2, 1970, pp. 165-166, abstract no. 72:100129 CAS. <i>abstract only</i>	
LCM	AH	SHIMADA, <i>Chemistry Letters</i> , no. 6, 1998, pp. 513-514, abstract no. 129:149031, CAS. <i>abstract only</i>	
LCM	AI	UTLEY, <i>Electroorganic Synthesis</i> , 1991, 377-386, abstract no. 116:129277, CAS. <i>abstract only</i>	


Examiner Signature	<i>L. Maier</i>	Date Considered	1-8-04
-----------------------	-----------------	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet	1	of	2	Application Number	10/023,603
				Filing Date	December 17, 2001
				First Named Inventor	Snyder <i>et al.</i>
				Group Art Unit	1646 1623
				Examiner Name	N/A L. Maier
				Attorney Docket Number	18085.105229 (EMU2090US)

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
LCM	AA	5,258,510		Ogawa <i>et al.</i>	11-02-1993	

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
LCM	AB	WO	91/05549		Ogawa <i>et al.</i>	02-05-1991		
LCM	AC	WO	94/04525		Ogawa <i>et al.</i>	03-03-1994		
LCM	AD	WO	94/12476		Kikuchi <i>et al.</i>	09-06-1994		
LCM	AE	WO	94/14796		Matsumoto <i>et al.</i>	07-07-1994		
LCM	AF	WO	94/20473		Matsuhisa <i>et al.</i>	15-09-1994		
LCM	AG	EP	0 470 514		Ogawa <i>et al.</i>	12-02-1992		
LCM	AH	EP	0 514 667		Ogawa <i>et al.</i>	25-11-1992		
LCM	AI	EP	0 533 240		Erb <i>et al.</i>	24-03-1993		
LCM	AJ	EP	0 533 242		Bock <i>et al.</i>	24-03-1993		
LCM	AK	EP	0 533 243		Gilbert <i>et al.</i>	24-03-1993		
LCM	AL	EP	0 533 244		Bock <i>et al.</i>	24-03-1993		
LCM	AM	EP	0 620 216		Setoi <i>et al.</i>	19-10-1994		

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
LCM	AN	ANDERSSON, K.E. <i>et al.</i> "Desomino-8-D-Arginine Vasopressin (DDAVP): Pharmacology and Clinical Use." <i>Drugs of Today</i> . 24(7):509-528, 1988.	


Examiner Signature		Date Considered	1-8-04
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		Application Number	10/023,603
		Filing Date	December 17, 2001
		First Named Inventor	Snyder <i>et al.</i>
		Group Art Unit	1646 1623
		Examiner Name	N/A L. Maier
		Attorney Docket Number	18085.105229 (EMU2090US)
Sheet	2	of	2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
LCM	BA	CALTABIANO, S., <i>et al.</i> "[d(CH <sub>2</sub> ) <sub>5</sub> Tyr(Me)]AVP." <i>Drugs of the Future</i> . 13(1):25-30, 1988.	
LCM	BB	LASZLO, F. A., <i>et al.</i> "Pharmacology and Clinical Perspectives of Vasopressin Antagonists." <i>Pharmacol. Rev.</i> 43(1):73-108, 1991.	
LCM	BC	LASZLO, F. A., <i>et al.</i> "Clinical Perspectives for Vasopressin Antagonists." <i>Drug News Perspect.</i> 6(8):591-599, 1993.	
LCM	BD	MIURA, Y., <i>et al.</i> "The effect of OPC-21268, an oral, nonpeptide arginine vasopressin V1 receptor antagonist, on a patient with congestive heart failure." <i>Clin. Nephrol.</i> 40(1):60-61, 1993.	
LCM	BE	NORTH, W.G. "Neuropeptide Production by Small Cell Carcinoma: Vasopressin and Oxytocin as Plasma Markers of Disease." <i>J. Clin. Endocrinol.</i> 73(6):1316-1320, 1991.	
LCM	BF	SEARLES, R.V., <i>et al.</i> "Effect of Intracameral (IC) Vasopressing (AVP) Infusion on Intraocular Pressure (IOP) During Head Down Tilt (HDT)." <i>Faseb J.</i> 8(5):A587(3398), March 18, 1994.	
LCM	BG	STUMP, D.L. <i>et al.</i> "The Use of Vasopressin in the Treatment of Upper Gastrointestinal Haemorrhage." <i>Drugs.</i> 39(1):38-53, 1990.	
LCM	BH	YAMAMURA, Y., <i>et al.</i> "Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V <sub>2</sub> receptor antagonist." <i>Br. J. Pharmacol.</i> 105:787-791, 1992.	
LCM	BI	YAMAMURA, Y., <i>et al.</i> "OPC-21268, An Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist." <i>Science.</i> 252:572-574, April 26, 1991.	

Examiner Signature		Date Considered	1-8-04
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.